FindTrial
Sign In

Randomized controlled study of bicarbonate-enhanced and conventional transarterial chemoembolization in treatment of hepatocellular carcinoma

Bicarbonate-enhanced and conventional transarterial chemoembolization for hepatocellular carcinoma

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-14005319
Enrollment
Unknown
Registered
2014-10-08
Start date
2014-03-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma

Interventions

cTACE:conventional transarterial chemoembolization
bTACE:bicarbonate-enhanced transarterial chemoembolization

Sponsors

The Second affiliated Hospital, Zhejiang University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Hepatocellular carcinoma is confirmed by tissue pathology or clinical diagnosis standard, and does not receive any therapy; 2. ECOG score 0-1; 3. HCC BCLC grading: B or C; 4. Child-Pugh score prior to therapy: A or B; 5. As judged by investigators, the patient can comply with the study protocol; 6. Patient voluntarily participates in this study, understands the process of the study, and is willing to sign the written consent form.

Exclusion criteria

Exclusion criteria: 1. HCC BCLC grading: 0, A or D; 2. Child-Pugh score prior to therapy: D; 3. Tumor invades liver and/or portal vein or their branches and there is evident vein artery shunt.

Design outcomes

Primary

MeasureTime frame
Tumor response rate;—

Secondary

MeasureTime frame
Survival time;—

Countries

China

Contacts

Public ContactXun Hu
Huxun@zju.edu.cn+86 0571 87783656

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 1, 2026